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E-cadherin Is an Additional Immunological Target for
Pemphigus Autoantibodies
Flor Evangelista1, David A. Dasher1, Luis A. Diaz1, Phillip S. Prisayanh1 and Ning Li1
Pemphigus foliaceus (PF) and pemphigus vulgaris (PV) are autoimmune blistering diseases characterized by
autoantibodies against desmoglein (Dsg)1 and Dsg3, respectively. The role of classical cadherins as
immunological targets of pemphigus autoantibodies is unknown. In this study, we tested the reactivity of
sera from patients with PF, Fogo Selvagem (FS), and PV by immunoprecipitation coupled with immunoblotting
(IP–IB) and ELISA techniques using a baculovirus-expressed ectodomain of E-cadherin. By IP–IB, anti-E-cadherin
reactivity was detected in all tested sera of PF (n¼ 13) and FS (n¼ 15) patients, and in 79% of mucocutaneous-
type PV patients (n¼ 33), but in none of the mucosal-type PV patients (n¼ 7). By ELISA, anti-E-cadherin IgG
was detected in most pemphigus sera that produced strong E-cadherin bands by IP–IB. The immunoreactivity of
PF/FS sera with E-cadherin was also demonstrated by IP–IB using human epidermal extracts. However,
immunofluorescence staining of A431DE cells (E-cadherin positive, Dsg1 negative) with pemphigus sera showed
negative results. Immunoadsorption and competitive ELISA analysis suggest that most of the anti-E-cadherin
antibodies cross-react with Dsg1, whereas others may represent independent antibodies that do not cross-react
with Dsg1. The functional relevance of these anti-E-cadherin IgG autoantibodies detected in these pemphigus
sera remains to be defined.
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INTRODUCTION
Adherens junctions and desmosomes are two intercellular
junctions in the epidermis that allow keratinocytes to adhere
to one another and maintain the integrity of the epithelium.
Classical cadherins (located in adherens junctions) and
desmosomal cadherins, sharing high sequence homology in
their ectodomain, play a particularly important role in the
dynamic regulation of intercellular adhesion (Patel et al.,
2003; Getsios et al., 2004; Gumbiner, 2005 [20]). E-cadherin
and P-cadherin are classical cadherins expressed in the
epidermis. E-cadherin is expressed in all layers of the
epidermis, whereas P-cadherin is limited to the basal cell
layer (Hirai et al., 1989). The desmosomal cadherins consist
of four desmogleins (Dsg1–Dsg4) and three desmocollins
(Dsc1–Dsc3), all encoded by separate genes. The expression
of different members of the desmosomal cadherins is tissue-
dependent and spatial-regulated (Getsios et al., 2004). Dsg1
and Dsc1 are the major desmosomal cadherins in the skin
where they are expressed throughout the epidermis but most
prominently in the upper layers. Expression of Dsg3 and Dsc3
is predominant in the lower epidermis and decreases
gradually toward the upper layers. Dsg1/Dsg3 and Dsc1/
Dsc3 are mostly restricted to the stratified epithelia,
whereas Dsg2 and Dsc2 are expressed ubiquitously in most
desmosome-containing tissues. The expression of Dsg2 in the
epidermis is low and mostly confined to the basal cell layer.
Dsg4 is a newly identified member of the Dsg family
expressed in the suprabasal layers of the epidermis (Kljuic
et al., 2003; Whittock and Bower, 2003).
Pemphigus is a group of autoimmune skin blistering
diseases characterized by pathogenic autoantibodies against
Dsg1 and Dsg3 with resultant loss of epithelial cell–cell
adhesion, known as acantholysis, leading to blister and
bulla formation (Stanley et al., 1984; Amagai et al., 1991).
Pemphigus vulgaris (PV) and pemphigus foliaceus (PF) are the
two classical forms of pemphigus (Lever, 1953). Fogo
Selvagem (FS) is an endemic form of PF found in certain
regions of Brazil where environmental factors may trigger
disease initiation and progression (Diaz et al., 1989). Blisters
and erosions on the skin and mucous membranes with
suprabasilar acantholysis seen histologically characterize PV,
whereas PF and FS affect only the skin and produce
subcorneal acantholysis (Lever, 1953). It is well established
that the sera of PF and FS patients possess anti-Dsg1 IgG
autoantibodies (Stanley et al., 1984, 1986), whereas the sera
of PV patients contain anti-Dsg3 IgG autoantibodies (Amagai
et al., 1991). On the basis of the clinical and the anti-Dsg
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autoantibody profile, PV is further divided into two subsets:
the mucosal type (mPV) and the mucocutaneous type (mcPV)
(Ding et al., 1997). Patients with mcPV exhibit mucosal and
skin disease clinically, with autoantibodies against Dsg1 and
Dsg3 detected by serological evaluation; mPV patients,
however, lack cutaneous disease and possess solely
anti-Dsg3 autoantibodies (Ding et al., 1997; Amagai et al.,
1999; Harman et al., 2001; Jamora et al., 2003). Passive
transfer of total IgG and affinity-purified anti-Dsg1 IgG or
anti-Dsg3 IgG from sera of patients with PF/FS or PV to
neonatal mice induces skin blisters in these animals that
mirror the key clinical and histological findings of each
corresponding human disease (Anhalt et al., 1982; Roscoe
et al., 1985; Amagai et al., 1992, 1995; Ding et al., 1999).
Anti-Dsg3 autoantibodies are detected in the sera of a
small number of PF/FS patients (o7%) (Arteaga et al., 2002).
Other desmosomal cadherins such as Dsc1–Dsc3 are
recognized by IgA antibodies from some clinical variants of
IgA pemphigus but not by typical PV or PF IgG (Hisamatsu
et al., 2004). Several additional antigens have also been
reported to react with some PV or PF sera. These include
Dsg4 (Kljuic et al., 2003; Nagasaka et al., 2004), pemphaxin
(Nguyen et al., 2000a), acetylcholine receptor (Nguyen et al.,
2000b), the a-chain of the high-affinity IgE receptor (Fiebiger
et al., 1998), and thyroid peroxidase (Pitoia et al., 2005).
In this study, we have evaluated the immunoreactivity of
PF, FS, and PV sera with baculovirus-expressed recombinant
E-cadherin. We found that many sera from patients with PF,
FS, and mcPV reacted with E-cadherin.
RESULTS
Construction and baculovirus expression of the ectodomains of
E-cadherin, Dsg1, and Dsg3
The recombinant baculovirus encoding the entire ectodomains
of human Dsg1 and Dsg3, each containing a C-terminal
histidine (His)-tag, had previously been constructed and
expressed as soluble proteins (Ding et al., 1997). For this study,
the recombinant baculovirus encoding the entire ectodomain of
human E-cadherin fused with a C-terminal His-tag was
generated. The three recombinant proteins were produced
as secreted forms in High Five cells infected by baculovirus.
Figure 1a depicts the immunoblot analysis of the culture
supernatants using a mouse monoclonal anti-His antibody
showing the presence of E-cadherin, Dsg1, and Dsg3. The
expression of E-cadherin was confirmed by immunoblot
analysis using a goat polyclonal antibody to human E-cadherin
(R&D Systems, Minneapolis, MN) (Figure 1b, lane 1).
E-cadherin ectodomain is recognized by PF and FS sera
Serum samples from PF (n¼ 13) and FS (n¼15) patients were
tested by immunoprecipitation coupled with immunoblotting
(IP–IB) for their immunoreactivity with the E-cadherin
ectodomain. All PF (13/13, 100%) and FS (15/15, 100%)
sera immunoprecipitated E-cadherin producing strong bands
by the majority of sera and weak bands by others. These
results are shown in Table 1 and Figure 2. As expected,
anti-Dsg1 autoantibodies were detected in all sera from PF
and FS patients with active disease. Anti-Dsg3 autoantibodies
were detected in only 1 out of 15 FS sera (7%) tested by IP–IB,
a finding that confirms a previous report (Arteaga et al.,
2002). PF sera did not react with Dsg3 by IP–IB.
The immunoreactivity of PF and FS sera with the
E-cadherin ectodomain was also tested by an E-cadherin
ELISA (Table 2). Using the cutoff point of 30, as determined
by receiver-operating characteristic (ROC) analysis (sensiti-
vity: 79% and specificity: 90%), we found positive tests in
46% of PF sera (n¼13) and 79% of FS sera (n¼ 89). The
majority of PF and FS sera exhibiting moderate-to-strong
E-cadherin bands by IP were also positive by ELISA (15 out of
1 2 3 1 2 3
Figure 1. Baculovirus expression of the ectodomain of human E-cadherin,
Dsg1, and Dsg3. IB analysis of the High Five culture supernatants containing
the secreted recombinant proteins E-cadherin (lane 1), Dsg1 (lane 2), and
Dsg3 (lane 3). Proteins were electrophoresed on 10% SDS-PAGE, transferred
to a nitrocellulose membrane, and probed with antibodies to the (a) His-tag or
(b) human E-cadherin.
Table 1. Prevalence of antibodies against E-cadherin,
Dsg1, and Dsg3 in pemphigus patients and controls by
IP-IB
IP positive
Number of
patients
Anti-
E-cadherin Anti-Dsg1 Anti-Dsg3
Pemphigus group
PF 13 13 (100%) 13 (100%) 0 (0%)
FS 15 15 (100%) 15 (100%) 1 (7%)
mPV 7 0 (0%) 0 (0%) 7 (100%)
mcPV 33 26 (79%) 28 (85%) 33 (100%)
Non-pemphigus group
BP 20 0 (0%) 3 (15%)1 0 (%)
SLE 3 0 (0%) 0 (0%) 0 (0%)
EBA 2 0 (0%) 0 (0%) 0 (0%)
Sezary syndrome 1 0 (0%) 0 (0%) 0 (0%)
Normal subjects 19 0 (0%) 0 (0%) 0 (0%)
BP, bullous pemphigoid; Dsg, desmoglein; EBA, epidermolysis bullosa
acquisita; FS, Fogo Selvagem; IB, immunoblotting; IP, immunoprecipita-
tion; mcPV, mucocutaneous-type pemphigus vulgaris; mPV, mucosal-
type pemphigus vulgaris; PF, pemphigus foliaceus; SLE, systemic lupus
erythematosus.
1One of the three BP sera was also positive by E-cadherin ELISA and Dsg1
ELISA (see also Table 2). The other two BP samples showed no anti-
E-cadherin autoantibodies by ELISA and IP.
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17 cases). Sera that produced weak IP bands were often
negative by ELISA (8 out of 11 cases) (Table 3). These results
may suggest that certain E-cadherin epitopes producing weak
bands by IP–IB were undetectable by ELISA.
The ectodomain of E-cadherin is recognized by sera from mcPV,
but not mPV, patients
A total of 40 PV sera from patients with active disease were
included in this study. Seven of these patients had mPV and
33 had mcPV. As summarized in Table 1, anti-Dsg3
autoantibodies were detected in the sera of all PV patients
(40 out of 40, 100%). Anti-Dsg1 autoantibodies were present
in 28 out of 33 mcPV sera (85%) and were absent in the sera
of 7 mPV patients (0%). Sera from 26 out of 33 mcPV patients
immunoprecipitated E-cadherin (79%). In contrast, the sera
from seven mPV patients did not bind E-cadherin. Repre-
sentative IP–IB results for the two types of PV are shown in
Figure 3a and b, respectively.
The E-cadherin ELISA analysis of the 40 samples of PV sera
is shown in Table 2. Using this assay, seven mPV sera
produced negative results. In contrast, 9 out of 33 mcPV
sera tested (27%) exhibited positive results. The low
percentage of positive E-cadherin sera by ELISA (27%,
Table 2) compared with the IP results (85%, see Table 1)
seem large owing to the sensitivity and nature of the two
assays. As summarized in Table 3, the majority of mcPV sera
that showed moderate-to-strong E-cadherin bands by IP
produced positive E-cadherin ELISA tests (8 out of 12,
67%). In contrast, 13 out of 14 mcPV sera (93%) that showed
weak E-cadherin binding by IP produced negative E-cadherin
ELISA results. Of note, 4 out of 12 mcPV sera that showed
strong (n¼1) or moderate (n¼3) E-cadherin bands by IP
produced negative ELISA results. This discrepancy may be
explained by differences in epitope availability in the setting
of IP, a true liquid-phase reaction, versus ELISA, a semiliquid-
phase assay.
Reactivity of E-cadherin ectodomain with sera from clinically
normal controls and patients with other diseases
A set of sera from patients with bullous pemphigoid (BP)
(n¼20), epidermolysis bullosa acquisita (n¼2), lupus
(n¼3), Sezary syndrome (n¼ 1), and normal subjects
(n¼19) were also tested by IP–IB for the presence of
E-cadherin
Dsg1
Dsg3
+ 1 2 3 4 5
PF FS
6 7 8 9 10 11 12–
Figure 2. Anti-E-cadherin IgG autoantibodies detected in PF and FS patients.
Representative IP–IB results from six PF (lanes 1–6) and six FS (lanes 7–12) sera
are shown. The E-cadherin- and Dsg1-recombinant proteins were
immunoprecipitated by all of the PF and FS sera, but none
immunoprecipitated Dsg3. Well-characterized serum samples from a PF or
PV patient were used as positive controls (þ ); normal human serum was used
as a negative control (). One PF serum (lane 3) and another FS (lane 7)
produced a weak E-cadherin band.
Table 2. Prevalence of antibodies against E-cadherin
by ELISA
Group of patients Number of patients
ELISA-positive
anti-E-cadherin
Pemphigus group
PF 13 6 (46%)
FS 89 70 (79%)
mPV 7 0 ( 0 % )
mcPV 33 9 (27%)
Non-pemphigus group
BP 20 1 (5%)1
SLE 3 0 (0%)
EBA 2 0 (0%)
Sezary syndrome 1 0 (0%)
Normal subjects 60 6 (10%)
BP, bullous pemphigoid; EBA, epidermolysis bullosa acquisita; FS, Fogo
Selvagem; mcPV, mucocutaneous-type pemphigus vulgaris; mPV, mucosal-
type pemphigus vulgaris; PF, pemphigus foliaceus; SLE, systemic lupus
erythematosus.
1This BP serum was also positive for Dsg1 autoantibodies by IP.
Table 3. Correlation between E-cadherin ELISA and
E-cadherin IP
PF/FS mcPV
Strong
IP (n=17)
Weak
IP (n=11)
Negative
IP (n=0)
Strong
IP (n=12)
Weak
IP (n=14)
Negative
IP (n=7)
ELISA (+) 15 (88%) 3 (27%) 0 8 (67%) 1 (7%) 0
ELISA () 2 (12%) 8 (73%) 0 4 (33%) 13 (93%) 7 (100%)
FS, Fogo Selvagem; IP, immunoprecipitation; mcPV, mucocutaneous-type
pemphigus vulgaris; PF, pemphigus foliaceus.
E-cadherin
Dsg1
Dsg3
+ 1 2 3
mPV mcPV
4 5 6– + 1 2 3 4 5 6 7 8 9 10–
Figure 3. Anti-E-cadherin IgG autoantibodies detected in PV patients.
Representative IP–IB results from (a) mPV and (b) mcPV sera are shown.
All PV sera reacted with Dsg3. E-cadherin was not recognized by mPV sera
but was bound by the majority of mcPV sera. A clear correlation between the
reaction with E-cadherin and Dsg1 was observed. The reaction varies from
strong reaction (lanes 1–3), moderate reaction (lanes 4, 8, and 9), weak
reaction (lane 5) to no reaction (lanes 6, 7, 10). (þ ) Positive control; (),
negative control.
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autoantibodies against Dsg1, Dsg3, and E-cadherin (Table 1).
A representative IP–IB is shown in Figure 4. None of the 45
non-pemphigus sera reacted with E-cadherin or Dsg3 by IP.
Three of the BP sera tested (n¼ 20) reacted weakly with Dsg1
using this assay (15%). One of the three Dsg1-positive BP sera
also reacted with E-cadherin by ELISA (Table 2). We and
others have reported that approximately 10% of BP sera
recognized Dsg1 (Ishii et al., 1997; Warren et al., 2000).
The same panel of non-pemphigus patients’ sera was also
tested by E-cadherin ELISA, and the results are shown in
Table 2. Using this assay, 6 out of 60 normal human sera
(10%) and 1 out of 20 BP sera (5%) produced positive results
(readings above 30). The six normal human sera that
produced positive E-cadherin ELISA scores were negative
by IP. The only E-cadherin ELISA-positive BP serum (n¼20)
was negative by IP for E-cadherin but positive for Dsg1. This
sample was a typical BP serum that stained the epidermal
side of salt-split skin at a titer of 1:640 but did not bind the
epidermal intercellular spaces as shown by indirect immuno-
fluorescence (IF) techniques.
Correlation between anti-E-cadherin and anti-Dsg1
autoantibodies tested by IP–IB
As shown in Table 4, a strong correlation was found between
the presence of anti-Dsg1 and anti-E-cadherin antibodies
in the sera of PF/FS (n¼28) and mcPV patients (n¼33). As
shown in this table, all Dsg1-positive PF/FS sera possess
anti-E-cadherin autoantibodies. On the other hand, five
mcPV sera and seven mPV sera with no detectable anti-
Dsg1 autoantibodies showed negative E-cadherin reactivity.
Only 2 out of 28 Dsg1-positive mcPV sera (7%) lacked anti-
E-cadherin autoantibodies by IP–IB.
Immunoadsorption studies
The possible cross-reactivity between anti-E-cadherin and
anti-Dsg1 was tested in four pemphigus sera by liquid-phase
immunoadsorption followed by IP–IB. As shown in Figure 5a,
preincubation of sera from an FS and a PF patient with control
culture supernatant (containing no recombinant Dsg1
(rDsg1)) did not affect the reactivity of E-cadherin (lanes
1 and 3). However, preincubation of these sera with a culture
supernatant containing rDsg1 eliminated the E-cadherin
reactivity (lanes 2 and 4). Similarly, preincubation of sera
from two mcPV patients (Figure 5b) with a culture super-
natant containing no recombinant proteins (lane 1) or rDsg3
(lane 3) did not abolish the E-cadherin reactivity. In contrast,
preincubation with rDsg1 inhibited the E-cadherin reactivity
(lane 2). These results indicated that at least in the four
pemphigus sera tested, anti-E-cadherin antibodies cross-
reacted with Dsg1.
To further determine whether all anti-Dsg1 antibodies
cross-reacted with E-cadherin, we performed a competitive
inhibition of the ELISA. As shown in Figure 6a, when eight
pemphigus sera (three PF and five FS) were preincubated with
E-cadherin and then tested by Dsg1-ELISA, there was minimal
inhibition of the binding (5–9%) of the anti-Dsg1 reactivity in
three sera (PF-3, FS-2, and FS-4) and a moderate inhibition
(22–38%) in five sera (PF-2, PF-4, FS-3, FS-5, and FS-6). These
results indicate that the majority of anti-Dsg1 autoantibodies
in these sera do not or minimally cross-react with E-cadherin.
Figure 6b shows the reverse experiment, that is, preincuba-
tion of the same set of sera with Dsg1 followed by
examination of the adsorbed sera by the E-cadherin ELISA.
As shown in this figure, preadsorption of these sera with Dsg1
reduced E-cadherin ELISA reactivity dramatically in three sera
(77–85% inhibition) (PF-2, PF-3, and PF-4), moderately in
three sera (47–64% inhibition) (FS-2, FS-3, and FS-6), and
minimally in two sera (7–12% inhibition) (FS-4 and FS-5).
These data indicate that not all anti-E-cadherin antibodies in
PF/FS sera cross-react with Dsg1.
Immunofluorescence staining of A431 by pemphigus sera
To test whether anti-E-cadherin autoantibodies present in
pemphigus sera recognize E-cadherin on cells, we performed
IF staining on A431D cells (E-cadherin negative) and A431DE
cells (E-cadherin positive). These two cell lines were
generated from the A431 cell line at Dr Margaret Wheelock’s
laboratory (Lewis et al., 1997). The A431 cell line was
originated from a human epithelial carcinoma and is known
to express E-cadherin and Dsg3, but not Dsg1 (Ishii et al.,
2005). We tested three pemphigus sera (two PF and one FS)
and none produced a consistent IF staining (data not shown).
PF sera recognize E-cadherin from normal human epidermal
extract
To demonstrate that anti-E-cadherin autoantibodies from
pemphigus sera also recognize native E-cadherin, we
immunoprecipitated this antigen from a human epidermal
E-cadherin
Dsg1
Dsg3
+ 1 2
Lupus BP sera
3 4 5 6 7 8 9 10 11 12–
Figure 4. IP–IB analysis of sera from patients with other diseases.
Representative results from sera of other diseases are shown: systemic lupus
erythematosus (lanes 1–3), epidermolysis bullosa acquisita (lane 4), Sezary
syndrome (lane 5), and BP (lanes 6–12). A weak positive reaction with two
BP sera to Dsg1 was detected (lanes 6 and 10). None of these sera reacted
with E-cadherin or Dsg3. (þ ) Positive control; () negative control.
Table 4. Correlation between antibodies against
E-cadherin and Dsg1 in pemphigus patients by IP-IB
PF/FS mcPV
Anti-Dsg1 (+)
(n=28)
Anti-Dsg1 (+)
(n=28)
Anti-Dsg1 ()
(n=5)
Anti-E-cadherin (+) 28 (100%) 26 (93%) 0 (0%)
Anti-E-cadherin () 0 (0%) 2 (7%) 5/5 (100%)
Dsg, desmoglein; FS, Fogo Selvagem; IB, immunoblotting; IP, immuno-
precipitation; mcPV, mucocutaneous-type pemphigus vulgaris; PF,
pemphigus foliaceus.
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extract with five pemphigus sera (four PF and one FS). The
immunoprecipitates were analyzed by IB using a mouse mAb
to human E-cadherin. As shown in Figure 7, all the five
pemphigus sera tested immunoprecipitated a 120-kDa
protein, which reacted with the mAb to E-cadherin (lanes
2–6). In contrast, a normal human serum failed to precipitate
E-cadherin (lane 1).
DISCUSSION
Experimental evidence accumulated over the last several
years supports the notion that the primary autoantibodies in
PF and PV are anti-Dsg1 and anti-Dsg3 IgG autoantibodies,
respectively. These autoantibodies are pathogenic (Anhalt
et al., 1982; Roscoe et al., 1985; Amagai et al., 1992, 1995;
Ding et al., 1999; Arteaga et al., 2002) and recognize
epitopes located on the EC1–2 domains of these desmosomal
cadherins (Sekiguchi et al., 2001; Li et al., 2003). Binding of
these pathogenic autoantibodies is calcium dependent and
conformation sensitive (Eyre and Stanley, 1987; Kowalczyk
et al., 1995). In this study, we provide in vitro evidence that a
classical cadherin, E-cadherin, is a possible additional
immunological target for pemphigus autoantibodies. Using
IP–IB analysis, the ectodomain of E-cadherin was recognized
by IgG from the sera of most PF, FS, and mcPV pemphigus
patients tested (Figures 2 and 3, Table 1). In contrast, sera
from normal controls or patients with other diseases such as
BP, epidermolysis bullosa acquisita, lupus, and Sezary
syndrome did not recognize E-cadherin (Figure 4). Interes-
tingly, anti-E-cadherin antibodies were detected only in
pemphigus patients with cutaneous disease (PF, FS, and
mcPV). Patients with mPV lacked anti-E-cadherin antibodies
by IP–IB analysis.
The presence of anti-E-cadherin antibodies in pemphigus
sera was also tested by ELISA (Table 2). The majority of sera
that produced strong to moderate E-cadherin bands by IP–IB
showed positive reaction by ELISA, whereas sera that reacted
weakly with E-cadherin by IP–IB were generally negative by
ELISA (Table 3). These results indicate that the IP–IB assay is
more sensitive to detect anti-E-cadherin antibodies than the
ELISA. The immunoreactivity of pemphigus sera with native
E-cadherin was further demonstrated by IP–IB using normal
1
1 2 3 1 2 3
2 3 4
PF-1FS-1
mcPV-1 mcPV-2
Figure 5. Elimination of E-cadherin IP reactivity in pemphigus serum by
preincubation with rDsg1. Sera samples from (a) FS and PF patients or
(b) mcPV patients were preincubated with a culture supernatant containing
rDsg1, rDsg3, or no recombinant protein and then IP with E-cadherin. The
precipitations were subjected to IB probed with a goat antiserum against
E-cadherin. As shown, preincubation with a culture supernatant containing no
recombinant protein did not affect the reactivity of E-cadherin (a, lanes
1 and 3; b, lane 1). However, preincubation with a culture supernatant
containing rDsg1 eliminated or greatly reduced the E-cadherin reactivity
(a, lanes 2 and 4; b, lane 2). In contrast, preincubation with a culture
supernatant containing rDsg3 did not affect the reactivity of E-cadherin
(b, lane 3).
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Figure 6. Competitive inhibition of the ELISA. A set of eight pemphigus
sera were (a) preincubated with purified recombinant E-cadherin and tested
for Dsg1 binding or (b) preincubated with purified rDsg1 and tested for
E-cadherin binding by ELISA. The black section of each bar shows the %
inhibition.
1 2 3 4 5 6
Figure 7. IP of normal human epidermal extracts with PF/FS sera. Epidermal
extracts from neonatal foreskins were immunoprecipitated with a normal
human serum (lane 1), PF sera (lanes 2–5), or an FS serum (lane 6)
and subjected to IB using a mouse mAb to human E-cadherin intracellular
domain. As shown, all the five patients’ sera precipitated the 120-kDa
E-cadherin (lanes 2–6). The normal human serum did not precipitate
E-cadherin (lane 1).
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human epidermal extracts (Figure 7). However, IF staining of
A431DE cells (E-cadherin positive but Dsg1 negative) using
three PF/FS sera produced unconvincing results (data not
shown). Two possible explanations may account for the
negative IF staining: (1) the epitopes recognized by pemphi-
gus anti-E-cadherin antibodies are masked in vivo, and (2) the
IF assay was not sensitive enough to detect the low levels of
autoantibodies in the sera of these patients.
The presence of anti-E-cadherin antibodies was correlated
with the presence of anti-Dsg1 autoantibodies in pemphigus
patients (Table 4). This observation suggests the possible
existence of a population of autoantibodies capable of
recognizing epitopes present on both antigens because of
the great degree of homology of these molecules. Indeed, the
IP reactivity of four pemphigus sera (two PF and two PV) with
E-cadherin was abolished upon adsorption with Dsg1 but not
with Dsg3 (Figure 5). Competitive ELISA analysis (Figure 6),
using another set of pemphigus sera (n¼ 8), suggests the
existence of at least three IgG autoantibody populations in
these sera. The first appears to encompass a large population
of anti-Dsg1 antibodies that do not cross-react with
E-cadherin (that is, they are not removed by E-cadherin
adsorption). The second comprises a small population of anti-
E-cadherin antibodies that do not cross-react with Dsg1 (that
is, they are not removed by Dsg1 adsorption). Finally, the
third comprises a small population of cross-reactive anti-
bodies that recognize both Dsg1 and E-cadherin. Ongoing
epitope mapping studies are aimed at verifying these
observations. Once epitope-specific anti-E-cadherin auto-
antibodies are available, it would be possible to explore their
pathogenicity by passive transfer studies in the experimental
mouse model of pemphigus (Anhalt et al., 1982)
The potential pathogenic role of the anti-E-cadherin
autoantibodies in pemphigus sera is as yet unknown.
However, several observations indicate that E-cadherin may
be involved in the pathogenesis of pemphigus acantholysis. It
has been shown that the expression of E-cadherin is markedly
reduced on acantholytic keratinocytes (Furukawa et al.,
1994) and increased in the serum of pemphigus patients
(Matsuyoshi et al., 1995). The addition of PV IgG to
keratinocyte cultures increases phosphorylation of E-cadherin
in addition to other desmosomal and adherens junctional
proteins such as Dsg3, b-catenin, and plakoglobin (Aoyama
et al., 1999; Nguyen et al., 2004), as well as p38MAPK and
heat-shock protein 27 (Berkowitz et al., 2005), a process
quite likely linked to the development of acantholysis. It is
also noteworthy that E-cadherin functions not only in
adhesion but also in desmosome assembly and cell signaling
(Lewis et al., 1997; Goodwin and Yap, 2004; Yin and Green,
2004). Antibodies blocking E-cadherin function are known to
affect desmosome assembly (Lewis et al., 1994) and promote
cell apoptosis (Fouquet et al., 2004), processes thought to
play roles in pemphigus acantholysis (Kitajima, 2002; Wang
et al., 2004; Calkins et al., 2006; Li et al., 2006). Another
intriguing observation is that upon binding of pemphigus
autoantibodies to the epidermal cell surface, widening of the
intercellular spaces in regions between the desmosomal
junctions, where E-cadherin is the major adhesive molecule
between keratinocytes (Horiguchi et al., 1994), precedes
desmosome splitting (Hashimoto and Lever, 1970; Takahashi
et al., 1985; Futamura et al., 1989; Horiguchi et al., 1994). It
is plausible that autoantibodies in PF/FS and mcPV may target
adhesion molecules in both desmosomes and adherens
junctions. An orchestrated dysfunction of both Dsg1-
mediated and E-cadherin-mediated adhesion may contribute
to pemphigus epidermal injury. This possibility needs to be
tested in future studies.
In conclusion, these studies provide in vitro evidence that
the majority of PF, FS, and mcPV sera possess IgG reactivity
to E-cadherin ectodomain. These findings underscore the
complexity and heterogeneity of the humoral response in
pemphigus autoimmunity and raise an open question of
whether this anti-E-cadherin reactivity in pemphigus sera is
relevant to disease.
MATERIALS AND METHODS
Sources of human sera
Sera from patients with PF (n¼ 13), FS (n¼ 89), PV (n¼ 40), BP
(n¼ 20), epidermolysis bullosa acquisita (n¼ 2), lupus (n¼ 3), and
Sezary syndrome (n¼ 1), as well as sera from clinically normal
individuals (n¼ 60), from the blood bank of the University of North
Carolina (UNC) were tested. Patients with PV were further divided
into two groups: those with mPV (n¼ 7) and those with mcPV
(n¼ 33). Diagnoses had previously been confirmed using established
clinical, histological, and serological criteria. This study was
approved by the Institutional Review Board at UNC. All clinical
investigation was conducted according to the Declaration of
Helsinki Principles. Participants gave their written informed consent.
Subcloning of the E-cadherin ectodomain into a baculovirus
expression vector
cDNA encoding the entire ectodomain of human E-cadherin was
amplified by PCR using a template of the full-length cDNA clone
constructed in a eukaryotic expression vector pcDNA3 (a generous
gift from Dr Barry M Gumbiner, Department of Cell Biology,
University of Virginia). The following pair of PCR primers was used
for amplification: forward primer: 50-cgcgcggccgccgccatgggcccttgga
gccgc-30; reverse primer: 50-gccgcatgcctacgcgtgatggtgatgatggtgcgcttg
caatcctgcttcgacag-30. For cloning purposes, restriction enzyme site
NotI or SphI was included in the forward and reverse primers,
respectively. A stop codon, as well as codons encoding a six-His tag,
was included in the reverse primer. The amplified PCR product was
digested with restriction enzymes NotI and SphI and then subcloned
into the baculovirus expression vector pFastBac1 (Life Technologies,
Gaithersburg, MD). The sequence of the subcloned E-cadherin was
confirmed by DNA sequencing. The coding region of the construct
begins with the endogenous initial Met followed by a putative signal
sequence to ensure the secretion of the expressed E-cadherin
ectodomain. An in-frame His-tag added to the C-terminus down-
stream of the EC5 domain was used to detect the recombinant
E-cadherin by IP using an mAb against the His-tag.
Generation of E-cadherin recombinant baculovirus
The recombinant baculovirus encoding human E-cadherin ecto-
domain was generated using the Bac-To-Bac baculovirus system
(Life Technologies), according to the procedure provided by the
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manufacturer. Briefly, the recombinant pFastBac1/E-Cad plasmid
was transformed into DH10Bac containing a bacmid (a baculovirus
shuttle vector) and a helper plasmid. Recombinant bacmid DNA was
then isolated from the positive clones and used to transfect Sf9 insect
cells cultured in Sf900-II serum-free medium (Life Technologies).
Culture supernatant containing recombinant baculovirus particles
was harvested after 72-hour transfection and used to generate a high
titer of viral stock by Sf9 cell infections.
Production of baculovirus-expressed E-cadherin, Dsg1, and
Dsg3
Soluble ectodomains of E-cadherin, Dsg1, and Dsg3 were produced
in High Five insect cells by infection with high-titer recombinant
baculovirus stocks of E-cadherin, Dsg1, and Dsg3 (Ding et al., 1997).
Optimal infection conditions for each recombinant protein were
determined by time-course studies with various multiplicities of
infections. Cell culture supernatants were harvested and dialyzed
against Tris-buffered saline (TBS; pH 7.2) containing 5mM Ca2þ .
Supernatants were stored at 80 1C until used for IP.
Immunoprecipitation coupled with immunoblotting
Aliquots of culture supernatants containing the baculovirus-ex-
pressed E-cadherin, Dsg1, or Dsg3 were incubated with 2 ml of
serum utilizing a previously described procedure (Li et al., 2003).
The precipitation was then subjected to SDS-PAGE and immuno-
blotted with an anti-His mAb coupled to horseradish peroxidase
(QIAGEN, Valencia, CA). The reacted protein was detected using
enhanced chemiluminescence reaction (ECL detection; Amersham
Biosciences, Piscataway, NJ). Well-characterized sera were used for
positive and negative controls for each assay.
Immunoadsorption studies
Liquid-phase immunoadsorption studies were carried out using sera
that produced optimal bands by IP–IB. Four sera were tested (one FS,
one PF, and two mcPV). Aliquots of FS and PF sera were preincubated
with culture supernatants containing rDsg1 (B500ng of protein) and
then tested by IP–IB against recombinant E-cadherin. Aliquots of
mcPV sera were incubated with either rDsg1 (B500ng of protein) or
rDsg3 (B500ng of protein) and then tested by IP–IB against
E-cadherin. Samples of FS, PF, and mcPV sera incubated with culture
supernatant lacking recombinant protein were included as controls.
Establishment of ELISA for E-cadherin
The baculovirus-expressed E-cadherin ectodomain was purified by
nickel affinity chromatography, according to the procedure
described by Ding et al. (1999), and used for the ELISA. An initial
chessboard titration experiment was carried out to determine the
optimal amounts of E-cadherin to coat the ELISA plate and the
dilutions of serum and secondary antibody conjugates to be used
(Figure S1). The immunomicrotiter plate (Costar, Cambridge, MA)
was coated with purified E-cadherin (200 ng per well) at 4 1C
overnight. After washing five times with TBS containing 3.7mM
Ca2þ and 0.05% Tween-20 (TBS/Ca2þ /T-20), the plate was blocked
with 1% BSA in TBS/Ca2þ /T-20 at room temperature for 1 hour. The
plate was then washed five times and incubated with duplicate
samples of diluted serum (1:200) for 1 hour at room temperature.
Following wash, the plate was incubated with a 1:1,500 dilution of
horseradish peroxidase-conjugated goat anti-human IgG (Bio-Rad,
Hercules, CA) for 1 hour. The color development was achieved with
the peroxidase substrate o-phenylenediamine. The index value was
defined according to Diaz et al. (2004). ROC analysis was performed
for the ELISA index values generated from a set of normal serum
(n¼ 60) and FS serum (n¼ 89) samples (Table S1; S2). An ROC curve
(Figure S2) was generated to display the sensitivity and specificity of
the ELISA. A cutoff of 30 produced a sensitivity of 79% and a
specificity of 90%. Index values above 30 were considered positive
throughout this investigation.
Competitive inhibition of ELISA
To study the possible cross-reactivity between anti-E-cadherin and
anti-Dsg1 autoantibodies, we tested a set of eight pemphigus sera
(three PF and five FS) using two ELISA competitive inhibition assays.
For the E-cadherin competitive assay, diluted serum was preincu-
bated with 2mg of purified recombinant E-cadherin in 100 ml of TBS/
Ca2þ /T-2/1% BSA at room temperature for 4 hours. The adsorbed
serum was then tested by Dsg1 ELISA as previously described
(Hilario-Vargas et al., 2006). For the Dsg1 competitive inhibition
assay, diluted serum was preincubated with 2 mg of purified rDsg1
and then tested by the E-cadherin ELISA. Sera preincubated with
buffer alone were included as non-absorbed controls. The competi-
tive inhibition of the ELISA binding was calculated for each serum
using the following formula: (% of inhibition)¼ (1OD of adsorbed
serum/OD of non-adsorbed serum) 100.
Cell culture and immunofluorescence staining
A431D and A431DE cell lines were kindly provided by Dr Margaret
Wheelock (University of Nebraska Medical Center, Omaha, NE).
Cells were cultured at 37 1C in a 5% CO2 atmosphere in DMEM/10%
fetal bovine serum containing 200mgml1 G418 as described (Lewis
et al., 1997). Cells were grown to confluence on glass coverslips and
used for IF staining using procedures described by Lewis et al. (1997)
and Amagai et al. (2000). Three pemphigus serum (two PF and
one FS) were tested at various dilutions (1:20 to 1:100) in duplicates.
A normal human serum and a commercial goat anti-human
E-cadherin ectodomain serum (R&D Systems) at 1:100 dilution were
included as a negative and a positive control, respectively.
IP–IB of human epidermal extract with pemphigus sera
Normal human epidermal sheets were obtained from neonatal
foreskins by heating the skin specimens at 56 1C for 30 seconds in
phosphate-buffered saline. The epidermal sheets were homogenized
and sonicated in 1% Nonidet P-40/TBS/Ca2þ containing 2mM
phenylmethylsulfonyl fluoride and a cocktail of protease inhibitors.
After centrifuge, the supernatant was diluted in TBS/Ca2þ and
subjected to IP using patients’ serum (four PF, one FS) and a normal
human serum as described (Li et al., 2003). The immunoprecipitate
was then subjected to SDS-PAGE and IB using a mouse mAb to
human E-cadherin intracellular domain (BD Biosciences, San Jose,
CA). The reacted protein was detected using enhanced chemilumi-
nescence reaction (ECL detection; Amersham Biosciences).
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